Mei Feng

Meifeng Biopharma is a leading Chinese biotechnology company specializing in the development and manufacture of high-end cell culture media and bioprocessing solutions. Founded in 2018 and headquartered in Beijing, the company provides a wide range of serum-free media products optimized for CHO, HEK293, and insect cell lines, supporting the production of antibodies, vaccines, and recombinant proteins. Meifeng also offers integrated CDMO services, including cell line development and process optimization, to help biopharmaceutical companies improve manufacturing efficiency and reduce costs. With a focus on innovation and quality, the company serves a diverse client base ranging from early-stage startups to large-scale pharmaceutical manufacturers. Meifeng's technology platform is designed to meet international regulatory standards, facilitating the global commercialization of biologics.